Fengyan Jin

4.4k total citations
69 papers, 1.4k citations indexed

About

Fengyan Jin is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Fengyan Jin has authored 69 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 29 papers in Hematology and 19 papers in Oncology. Recurrent topics in Fengyan Jin's work include Multiple Myeloma Research and Treatments (22 papers), Protein Degradation and Inhibitors (14 papers) and Angiogenesis and VEGF in Cancer (8 papers). Fengyan Jin is often cited by papers focused on Multiple Myeloma Research and Treatments (22 papers), Protein Degradation and Inhibitors (14 papers) and Angiogenesis and VEGF in Cancer (8 papers). Fengyan Jin collaborates with scholars based in China, Germany and United States. Fengyan Jin's co-authors include Dirk M. Hermann, Thorsten R. Doeppner, Yun Dai, Ulf Brockmeier, Anil Zechariah, Eric Metzen, Friedrich Otterbach, Nina Hagemann, Iris Helfrich and Ayman ElAli and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Fengyan Jin

61 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fengyan Jin China 24 660 298 295 271 265 69 1.4k
Courtney T. Griffin United States 22 1.0k 1.6× 244 0.8× 333 1.1× 175 0.6× 247 0.9× 50 2.0k
Kenichiro Yata Japan 19 548 0.8× 103 0.3× 366 1.2× 360 1.3× 237 0.9× 54 1.4k
Enming J. Su United States 19 491 0.7× 337 1.1× 228 0.8× 75 0.3× 163 0.6× 36 1.4k
José Carlos Rivera Canada 26 823 1.2× 182 0.6× 136 0.5× 88 0.3× 237 0.9× 53 2.1k
Eloy Cuadrado Spain 18 586 0.9× 294 1.0× 129 0.4× 146 0.5× 364 1.4× 29 1.5k
Zheqing Cai United States 14 815 1.2× 580 1.9× 277 0.9× 262 1.0× 127 0.5× 17 2.0k
Hua Teng China 18 570 0.9× 266 0.9× 67 0.2× 99 0.4× 146 0.6× 42 1.1k
Émilie Picard France 23 923 1.4× 171 0.6× 68 0.2× 442 1.6× 387 1.5× 58 2.1k
Erika Folestad Sweden 12 353 0.5× 151 0.5× 98 0.3× 131 0.5× 108 0.4× 16 927

Countries citing papers authored by Fengyan Jin

Since Specialization
Citations

This map shows the geographic impact of Fengyan Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengyan Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengyan Jin more than expected).

Fields of papers citing papers by Fengyan Jin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengyan Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengyan Jin. The network helps show where Fengyan Jin may publish in the future.

Co-authorship network of co-authors of Fengyan Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Fengyan Jin. A scholar is included among the top collaborators of Fengyan Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengyan Jin. Fengyan Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yue, Tingting, et al.. (2025). Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma. Blood Reviews. 70. 101256–101256. 3 indexed citations
2.
Xu, Weiling, Yiwen Bu, Min Zeng, et al.. (2025). Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study. Hematological Oncology. 43(4). e70112–e70112.
3.
Xu, Weiling, Xinyue Liang, Shanshan Liu, et al.. (2024). Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis. Clinical Medicine. 24(6). 100252–100252.
4.
5.
Liang, Xinyue, Weiling Xu, Wenyang Huang, et al.. (2022). Proposed risk‐scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma. American Journal of Hematology. 98(2). 251–263. 8 indexed citations
6.
Yang, Hongmei, Yue Sun, Qingchao Li, Fengyan Jin, & Yun Dai. (2022). Diverse Epigenetic Regulations of Macrophages in Atherosclerosis. Frontiers in Cardiovascular Medicine. 9. 868788–868788. 31 indexed citations
7.
Jin, Fengyan, Jian Li, Jianfeng Guo, et al.. (2021). Targeting epigenetic modifiers to reprogramme macrophages in non-resolving inflammation-driven atherosclerosis. European Heart Journal Open. 1(2). oeab022–oeab022. 27 indexed citations
8.
Jin, Fengyan, et al.. (2021). The mechanisms and therapeutic targets of ferroptosis in cancer. Expert Opinion on Therapeutic Targets. 25(11). 965–986. 37 indexed citations
9.
Ding, Xiao, Wenyang Huang, Yi Peng, et al.. (2020). Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma. Annals of Hematology. 99(6). 1331–1339. 8 indexed citations
10.
Dong, Yujun, Chunrui Li, Wenrong Huang, et al.. (2020). [Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma: a multi-center retrospective study].. PubMed. 41(1). 10–15. 2 indexed citations
11.
Zang, Meirong, Jiaojiao Guo, Lanting Liu, et al.. (2020). Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s. Oncogenesis. 9(3). 31–31. 11 indexed citations
12.
Wu, Chuan, Ting Yang, Yingmin Liu, et al.. (2018). ARNT/HIF‐1β links high‐risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. Cancer Medicine. 7(8). 3899–3911. 30 indexed citations
13.
Su, Long, Yehui Tan, Hai Lin, et al.. (2018). Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance. Oncotarget. 9(38). 24970–24979. 34 indexed citations
14.
Jin, Fengyan, Nina Hagemann, Li Sun, et al.. (2018). High-density lipoprotein (HDL) promotes angiogenesis via S1P3-dependent VEGFR2 activation. Angiogenesis. 21(2). 381–394. 40 indexed citations
15.
Doeppner, Thorsten R., Britta Kaltwasser, Fengyan Jin, et al.. (2018). Very Delayed Remote Ischemic Post-conditioning Induces Sustained Neurological Recovery by Mechanisms Involving Enhanced Angioneurogenesis and Peripheral Immunosuppression Reversal. Frontiers in Cellular Neuroscience. 12. 383–383. 37 indexed citations
16.
Zhang, Qi, Thorsten R. Doeppner, Feng Niu, et al.. (2015). LDL suppresses angiogenesis through disruption of the HIF pathway via NF-κB inhibition which is reversed by the proteasome inhibitor BSc2118. Oncotarget. 6(30). 30251–30262. 16 indexed citations
17.
Sun, Yunpeng, Jingnan Sun, Wen Xue, et al.. (2015). Bioinformatics analyses of differentially expressed genes associated with bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. OncoTargets and Therapy. 8. 2681–2681. 13 indexed citations
18.
Jin, Fengyan, Ulf Brockmeier, Friedrich Otterbach, & Eric Metzen. (2012). New Insight into the SDF-1/CXCR4 Axis in a Breast Carcinoma Model: Hypoxia-Induced Endothelial SDF-1 and Tumor Cell CXCR4 Are Required for Tumor Cell Intravasation. Molecular Cancer Research. 10(8). 1021–1031. 107 indexed citations
19.
Jin, Fengyan, Huifan Ji, Chunshu Jia, et al.. (2012). Synergistic Antitumor Effects of Endostar in Combination with Oxaliplatin via Inhibition of HIF and CXCR4 in the Colorectal Cell Line SW1116. PLoS ONE. 7(10). e47161–e47161. 17 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Courtney T. Griffin Breakdown of academic impact, for papers by Kenichiro Yata Breakdown of academic impact, for papers by Enming J. Su Breakdown of academic impact, for papers by José Carlos Rivera Breakdown of academic impact, for papers by Eloy Cuadrado Breakdown of academic impact, for papers by Zheqing Cai Breakdown of academic impact, for papers by Hua Teng Breakdown of academic impact, for papers by Émilie Picard Breakdown of academic impact, for papers by Erika Folestad
Rankless by CCL
2026